527 | HIGH‐THROUGHPUT T CELL RECEPTOR SEQUENCING TO DETECT MEASURABLE RESIDUAL DISEASE IN SYSTEMIC T CELL LYMPHOMA TREATED WITH BRENTUXIMAB VEDOTIN: A PROSPECTIVE TRIAL
Michael P. Randall(Dartmouth College), Weiyun Z. Ai(City College of San Francisco), Jasmine Zain(City of Hope), M. Gallucci(Adaptive Biotechnologies (United States)), Charalambos Andreadis(University of California, San Francisco), Bita Fakhri(University of California, San Francisco), Mukund Seshadri(Roswell Park Comprehensive Cancer Center), Zachary R. Barbati(Harvard University), Nahid Razi(University of California, San Francisco), H. T. Simmons(Royal College of Surgeons of England), Linh Truong(University of California, San Francisco), Michael A. Spinner(Stanford Medicine), Beth E. Dunning, Jasmine C. Wong(University of California, San Francisco)
Cited by 0
Related Papers
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
|Journal of Clinical Oncology|2010|487